Stereotaxis, Inc. (Nasdaq: STXS) announced today that its new capital order momentum continued to build in the second quarter of 2010. The Company generated new capital orders of $10.2 million, more than doubling new capital orders from the 2009 second quarter and representing a 42% sequential increase over orders in the first quarter of 2010. New orders from North America totaled $5.1 million of the total orders in the quarter.
"Our new capital order momentum in the quarter validates our view that driving clinical adoption builds both procedure revenue and market interest," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. "The largest increase was in North America where we have focused on clinical adoption. As a result, procedures in the U.S. are steadily increasing, resulting in higher utilization and stronger reference sites. In addition, we continue to generate a strong and balanced performance from Europe and the rest of the world."